ReviewEuropean journal of nuclear medicine and molecular imaging2021
Factors predicting biochemical response and survival benefits following radioligand therapy with [
Review in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Outcome-driven dosimetry optimization for [European journal of nuclear medicine and molecular imaging · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- PSMA-PET response under [European journal of nuclear medicine and molecular imaging · 2026Article
- Prompt PSA changes as a prognostic marker for response to PSMA-radioligand therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Refining the clinical utility of [European journal of nuclear medicine and molecular imaging · 2026Article
- AI-driven body composition monitoring and its prognostic role in mCRPC undergoing lutetium-177 PSMA radioligand therapy: insights from a retrospective single-center analysis.EJNMMI research · 2025Article
- Influence of dosimetry accuracy on the correlation with treatment outcome in a preliminary PSMA radiopharmaceutical therapy study.European journal of nuclear medicine and molecular imaging · 2025Article
- RECIP 1.0 + PSA for response assessment in mCRPC patients treated withEJNMMI research · 2025Article
- Predicting Response to [177Lu]Lu-PSMA Therapy in mCRPC Using Machine Learning.Journal of personalized medicine · 2024Article
- Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [The Indian journal of radiology & imaging · 2024Article
- Quantification of biochemical PSA dynamics after radioligand therapy with [EJNMMI physics · 2024Article
- Review
- MulticentricFrontiers in nuclear medicine · 2023Article
- Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials.Therapeutic advances in medical oncology · 2023Review
- Novel radionuclide therapy combinations in prostate cancer.Therapeutic advances in medical oncology · 2023Review
- Optimized TherapeuticPharmaceuticals (Basel, Switzerland) · 2022Article
- Pharmacological Optimization of PSMA-Based Radioligand Therapy.Biomedicines · 2022Review
- Baseline Imaging Derived Predictive Factors of Response Following [Biomedicines · 2022Article
- Predictive and prognostic potential of pretreatmentFrontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PC) is one of the most common cancers in men. Although the overall prognosis is favorable, the management of metastatic castration-resistant prostate cancer (mCRPC) patients is challenging. Usually, mCRPC patients with progressive disease are considered for radioligand therapy (RLT) after exhaustion of other standard treatments. The prostate-specific membrane antigen (PSMA) labeled with Lutetium-177 ([
methodsStudies were retrieved by searching MEDLINE/PubMed and GoogleScholar. The search keywords were as follows: {("177Lu-PSMA") AND ("radioligand") AND ("prognosis") OR ("predict")}. Studies discussing one or more factors which may be prognostic or predictive of response to [
resultsSeveral demographic, histological, biochemical, and imaging factors have been assessed as predictive parameters for the response to thistreatment; however, the evaluated factors were diverse, and the results mostly were divergent, except for the PSA level reduction after treatment, which unanimously predicted prolonged survival.
conclusionSeveral studies have investigated a multitude of factors to detect those predicting response to [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.